CytomX Therapeutics, Inc. (NASDAQ:CTMX) is among the 11 Most Active Small Cap Stocks to Buy. On March 18, CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw Jefferies raise its price target to $16 from $8 while maintaining a Buy rating following encouraging Phase 1 data for its lead asset Varseta-M in late-line metastatic colorectal cancer. The analyst highlighted the therapy’s potential as a differentiated antibody-drug conjugate (ADC), estimating a commercial opportunity exceeding $1 billion in later-line sett ...

This week's biotech landscape witnessed key FDA approvals, rejections, NDA resubmissions, merger terminations, trial discontinuations, and clinical trial data readouts across therapeutic areas such as Turner Syndrome, Late-Line Colorectal Cancer, Obesity, and Type 1 Diabetes. Let us unpack the key developments and milestones in the biotech space this week. FDA and EU Approvals & Rejections GSK's Lynavoy Wins FDA Approval for Cholestatic Pruritus in PBC GSK plc (GSK), secured for Lynavoy, the first U.S. tre ...

On Tuesday, CytomX Therapeutics announced a public offering of 45.9 million shares at $5.30 per share, pre-funded warrants to purchase 1.179 million shares.The company will use the proceeds for the continued development of Varseta-M and other pipeline programs.CytomX Colorectal Data Shows 32% ResponseThe company’s stock rallied following recent data on colorectal cancer treatment.The latest data revealed positive response rates in colorectal cancer patients, with expansion cohorts showing a 32% response rat ...

Ending 2025, I wrote with optimism about the status of CytomX Therapeutics ( CTMX ) probody treatment approach to cancer, despite rises in market sentiment throughout the year. Now they have reportedI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in t ...

Core Viewpoint - CytomX Therapeutics, Inc. has announced a public offering of 45,990,567 shares of common stock priced at $5.30 per share, aiming to raise approximately $250 million in gross proceeds for the development of its pipeline programs, including Varseta-M [1][2]. Group 1: Offering Details - The offering includes pre-funded warrants for certain investors to purchase an additional 1,179,245 shares of common stock [1]. - Underwriters have a 30-day option to purchase up to an additional 7,075,471 shares at the public offering price [1]. - The closing of the offering is expected on March 19, 2026, subject to customary closing conditions [1]. Group 2: Use of Proceeds - Net proceeds from the offering will be used for the continued development of Varseta-M and other pipeline programs [2]. - Remaining net proceeds will be allocated for capital expenditures, working capital, and general corporate purposes [2]. Group 3: Company Overview - CytomX is a clinical-stage biopharmaceutical company focused on developing conditionally activated, masked PROBODY® therapeutics for cancer treatment [5]. - The company's pipeline includes Varseta-M, an antibody-drug conjugate targeting EpCAM, and CX-801, a masked interferon alpha-2b PROBODY® cytokine [5]. - Varseta-M is being developed for metastatic colorectal cancer, while CX-801 targets metastatic melanoma [5]. - CytomX has established collaborations with major oncology leaders such as Amgen, Bristol Myers Squibb, Regeneron, and Moderna [5].

Core Viewpoint - CytomX Therapeutics, Inc. has announced a proposed public offering of up to $250 million to support the development of its pipeline, including the promising Varseta-M program [1][2] Group 1: Offering Details - The public offering includes common stock and pre-funded warrants, with an option for underwriters to purchase an additional $37.5 million in shares [1] - The offering is managed by Jefferies, Piper Sandler, Cantor, and Barclays, with Wedbush PacGrow as co-manager [2] - A shelf registration statement was filed with the U.S. Securities and Exchange Commission, effective immediately [2] Group 2: Pipeline and Collaborations - CytomX's pipeline features Varseta-M, an antibody-drug conjugate targeting EpCAM for advanced colorectal cancer, developed in collaboration with ImmunoGen [2] - Another candidate, CX-801, is a masked interferon alpha-2b PROBODY® cytokine targeting metastatic melanoma [2] - The company has strategic collaborations with Amgen, Bristol Myers Squibb, Regeneron, and Moderna [3] Group 3: Financial Performance and Market Reaction - The stock experienced high volatility following the offering announcement and positive Phase 1 data for Varseta-M, which showed confirmed response rates of 32% at 10 mg/kg and 20% at 8.6 mg/kg [3] - As of March 17, 2026, CTMX trades around $5.82–$6.53, with a market capitalization of approximately $400 million [4] - Trading volume was extremely high, with over 121 million shares traded on March 16, driven by the offering news and earnings update [4]

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Today, I am putting CytomX Therapeutics, Inc. ( CTMX ) in the spotlight. The stock jumped by nearly 45% on Monday after posting Q4 results before the bell. Management also launched a large secondary offering to raise additional funding ...

Key Takeaways CTMX shares jumped 44% after strong phase I expansion data for Varseta-M in late-line metastatic CRC.CTMX reported response rates rising from 6% to 32% across dose levels, with disease control reaching 88%.CTMX plans FDA talks to align on a registrational CRC study and plans new studies with Avastin combos.Shares of CytomX Therapeutics (CTMX) soared 44.2% on Monday after the company reported positive phase I expansion data for its EpCAM-targeting PROBODY ADC, varsetatug masetecan (Varseta-M), ...

Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team ...

CytomX Therapeutics (NASDAQ:CTMX), a biotech company that develops conditionally activated biologics for cancer treatment, closed Monday at $6.75, up 44.23%. The stock is jumping after releasing Phase 1 Varseta-M data in metastatic colorectal cancer and subsequent upbeat analyst reactions. Investors will now be watching upcoming FDA interactions and further clinical readouts.Trading volume reached 118 million shares, coming in about 2,211% above its three-month average of 5.1 million shares. CytomX IPO'd in ...